Svenungsson B, Ekwall E, Hansson H B
Department of Infectious Diseases, Karolinska Institute, Roslagstull Hospital, Stockholm, Sweden.
Infection. 1990 May-Jun;18(3):163-5. doi: 10.1007/BF01642105.
In a randomized, double blind, placebo-controlled study 36 patients aged 16-77 years who had been carriers of nontyphi Salmonella species for 10-21 weeks were given the combination pivampicillin/pivmecillinam or placebo for four weeks in order to eradicate the carrier state. 34/36 patients who fulfilled the criteria for inclusion in the study were evaluable for efficacy, 16 in the pivampicillin/pivmecillinam group and 18 in the placebo group. Seven patients in the pivampicillin/pivmecillinam group had to terminate the treatment after 10-25 days because of adverse reactions, mainly exanthema and nausea. After therapy 8/16 patients treated with pivampicillin/pivmecillinam and 4/18 patients treated with placebo had negative stool cultures for Salmonella species during a mean follow-up time of 13 and 20 weeks, respectively. No abnormalities could be found in those patients who did not respond to therapy except for earlier cholecystectomy in two patients, both in the pivampicillin/pivmecillinam group.
在一项随机、双盲、安慰剂对照研究中，36名年龄在16至77岁之间、已携带非伤寒沙门氏菌10至21周的患者接受了匹氨西林/匹美西林联合用药或安慰剂治疗，为期四周，以消除携带状态。符合研究纳入标准的34/36名患者可进行疗效评估，匹氨西林/匹美西林组16名，安慰剂组18名。匹氨西林/匹美西林组的7名患者因不良反应（主要为皮疹和恶心）在10至25天后不得不终止治疗。治疗后，接受匹氨西林/匹美西林治疗的8/16名患者和接受安慰剂治疗的4/18名患者在平均随访时间分别为13周和20周时，粪便沙门氏菌培养呈阴性。除了匹氨西林/匹美西林组的两名患者曾接受过胆囊切除术外，未对治疗产生反应的患者未发现异常情况。
